https://scholars.lib.ntu.edu.tw/handle/123456789/434974
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHIA-YU CHU | en_US |
dc.creator | Chia-Yu Chu | - |
dc.date.accessioned | 2019-12-04T08:44:09Z | - |
dc.date.available | 2019-12-04T08:44:09Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0926-9959 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33947378220&doi=10.1111%2fj.1468-3083.2006.01991.x&partnerID=40&md5=62da3382f5ec00522c2328beb603bd25 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/434974 | - |
dc.description.abstract | Background: Steroid-induced rosacea-like eruption is characterized by facial rosacea-like dermatitis in patients that have been treated with topical steroids for relatively long periods. Objective: To evaluate the efficacy and tolerability of 1% pimecrolimus topical cream for steroid-induced rosacea-like eruption. Methods: In anopen-label pilot study, 40 patients were enrolled and instructed to apply 1% pimecrolimus cream twice daily for 6 weeks. Patients were evaluated by a rosacea clinical score, investigator's global assessment, overall erythema severity, and tolerability at weeks 0, 2, and 6. Results: In 35 patients, the rosacea clinical score decreased significantly from 16.0 ± 4.3 at baseline to 8.1 ± 3.3 at week 2 and 4.2 ± 2.5 at week 6 (P < 0.0001). Investigator's global assessment was 4.1 ± 1.1 (baseline), then decreased to 1.4 ± 0.8 (week 2) and 0.5 ± 0.6 (week 6) (P < 0.0001). By week 6, 48.6% of the patients were clear. Overall erythema severity was 2.4 ± 0.7 (baseline), 0.9 ± 0.4 (week 2), and 0.3 ± 0.4 (week 6) (P < 0.0001). Cutaneous adverse events (local burning, stinging, and itching) occurred in 17.5%. Conclusion: Pimecrolimus cream might be efficacious, safe, and well tolerated for steroid-induced rosacea-like eruption. The small sample size and open label nature of this study is its limitation. Further double-blind, vehicle-controlled studies are needed. ? 2007 The AuthorJournal compilation ? 2007 European Academy of Dermatology and Venereology. | - |
dc.relation.ispartof | Journal of the European Academy of Dermatology and Venereology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | corticosteroid; fluorinated steroid; pimecrolimus; adolescent; adult; aged; article; burning sensation; clinical assessment; cream; disease severity; drug efficacy; drug induced disease; drug safety; drug tolerability; drug withdrawal; erythema; female; human; male; open study; pilot study; priority journal; pruritus; rosacea; sample size; scoring system; skin manifestation; steroid therapy; treatment duration; Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Calcineurin; Dermatologic Agents; Drug Eruptions; Erythema; Facial Dermatoses; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Satisfaction; Pilot Projects; Rosacea; Safety; Tacrolimus; Telangiectasis; Treatment Outcome | - |
dc.title | An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1111/j.1468-3083.2006.01991.x | - |
dc.identifier.pmid | 17373975 | - |
dc.identifier.scopus | 2-s2.0-33947378220 | - |
dc.relation.pages | 484-490 | - |
dc.relation.journalvolume | 21 | - |
dc.relation.journalissue | 4 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Dermatology | - |
crisitem.author.dept | Dermatology-NTUH | - |
crisitem.author.orcid | 0000-0002-9370-3279 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。